Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI

Five-year event-free survival in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) currently exceeds 80-85%. However, 15-20% of patients still experience a relapsed/refractory disease. From 1 January 2015 to 31 December 2020, thirty-nine patients, 0-21 years old with r/r BCP-ALL were treated with blinatumomab with the aim of inducing remission ( n = 13) or reducing MRD levels ( n = 26) in the frame of different multiagent chemotherapy schedules, in seven AIEOP centers. Patients were treated in compassionate and/or off-label settings and were not enrolled in any controlled clinical trials. Treatment was well tolerated; 22 (56.4%) patients reported adverse events (AE) on a total of 46 events registered, of which 27 (58.7%) were ≤2 grade according to CTCAE. Neurological AEs were 18 (39.1%); only two patients required transient blinatumomab discontinuation. Complete remission (CR) rate was 46% for the 13 patients treated with ≥5% blasts and 81% PCR/FC MRD negativity in the 26 patients with blasts < 5%. Median relapse-free survival was 33.4 months (95% CI; 7.5-59.3); median overall survival was not reached over a mean follow-up of 16 months. In our study, as in other real-life experiences, blinatumomab proved to be effective and well-tolerated, able to induce a high rate of CR and MRD negativity.

N Engl J Med. 2017 Mar 2;376(9):836-847. (PMID: 28249141)
Curr Med Chem. 2017;24(11):1050-1065. (PMID: 28088906)
Cancer. 2019 Dec 01;125(23):4181-4192. (PMID: 31433496)
Pediatr Blood Cancer. 2021 Jan;68(1):e28718. (PMID: 33098744)
Ther Adv Hematol. 2020 Jun 2;11:2040620720927575. (PMID: 32537116)
JAMA. 2021 Mar 2;325(9):833-842. (PMID: 33651090)
Br J Haematol. 2020 Sep;190(5):764-771. (PMID: 32314348)
Leukemia. 2020 Sep;34(9):2473-2478. (PMID: 32094465)
JAMA. 2021 Mar 2;325(9):843-854. (PMID: 33651091)
Eur J Haematol. 2021 Apr;106(4):473-483. (PMID: 33320384)
Front Med. 2020 Dec;14(6):689-700. (PMID: 33074527)
Pediatr Blood Cancer. 2022 Apr;69(4):e29562. (PMID: 35044079)
Pediatr Blood Cancer. 2021 May;68(5):e28922. (PMID: 33638292)
Haematologica. 2020 Sep 10;105(11):2524-2539. (PMID: 33054110)
Cancer Res. 2020 Jan 1;80(1):91-101. (PMID: 31662326)
Oncologist. 2018 Nov;23(11):1366-1371. (PMID: 30018129)
J Clin Oncol. 2014 Dec 20;32(36):4134-40. (PMID: 25385737)
Blood Cancer J. 2020 Jul 24;10(7):77. (PMID: 32709851)
N Engl J Med. 2015 Oct 15;373(16):1541-52. (PMID: 26465987)
Blood. 2020 Oct 15;136(16):1803-1812. (PMID: 32589723)
Front Oncol. 2014 Mar 31;4:63. (PMID: 24744989)
Expert Rev Hematol. 2018 Dec;11(12):945-956. (PMID: 30358451)
Neoplasma. 2020 Nov;67(6):1424-1430. (PMID: 32701357)
J Clin Oncol. 2016 Dec 20;34(36):4381-4389. (PMID: 27998223)
Mol Immunol. 2006 Mar;43(8):1129-43. (PMID: 16139892)
J Clin Med. 2021 Jun 08;10(12):. (PMID: 34201368)
J Clin Oncol. 2017 Jun 1;35(16):1795-1802. (PMID: 28355115)
Lancet Oncol. 2015 Jan;16(1):57-66. (PMID: 25524800)
Blood. 2012 Oct 4;120(14):2807-16. (PMID: 22896001)
Lancet Oncol. 2013 May;14(6):e205-17. (PMID: 23639321)
Cancer Metastasis Rev. 2019 Dec;38(4):595-610. (PMID: 31811553)
Blood. 2018 Apr 5;131(14):1522-1531. (PMID: 29358182)
JAMA. 2021 Mar 2;325(9):830-832. (PMID: 33651075)

Keywords: acute lymphoblastic leukemia; pediatric; real-life experience; relapse; targeted therapy; toxicity

Date Created: 20220121 Latest Revision: 20240405

20250114

PMC8773489

10.3390/cancers14020426

35053589